Compare HCA Health Inc (HCA) vs L3Harris Technologies Inc (LHX) Price & Performance

HCA Healthcare (HCA) trades at $439.17, up 1.61% today, with a bullish technical signal and strong fundamental performance. Revenue grew to $75.6 billion in 2025, with net income reaching $6.78 billion, and the company has beaten EPS estimates for three consecutive quarters. Recent news includes an upcoming Q3 2026 earnings call and the completion of the College of Health Care Professions acquisition, highlighting operational expansion.

The outlook remains positive with a consensus price target of $461.12, though risks include ongoing legal investigations and high debt levels. Earnings growth and cost controls support upside potential, but investors should monitor regulatory developments and payer-mix pressures that could impact margins.

LHX trades at $233.63, down 1.79% for the day, amid bearish technical signals but strong fundamental performance. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $3.13 exceeding the $2.80 estimate. Recent contract wins totaling over $10 billion for THAAD and PAC-3 MSE propulsion systems provide substantial revenue visibility, while analyst consensus remains strongly bullish with a $340 price target representing 45% upside potential.

The investment case balances strong defense contracting fundamentals against technical weakness and legal overhangs. While operational performance and contract backlog support long-term growth, multiple law firm investigations create near-term uncertainty. The stock's current valuation at 23.93x P/E appears reasonable given projected 8.11% net margins and defense budget tailwinds, but requires monitoring of legal developments and execution on major contracts.